CMS selects next batch of 15 high-cost medicines for third negotiation cycle
The Centers for Medicare & Medicaid Services (CMS) has announced the next 15 high-cost medicines up for price negotiations under the …
Post
-
-
FDA accepts Otsuka’s centanafadine application for ADHD treatment
The US Food and Drug Administration (FDA) has accepted for priority review Otsuka Pharmaceutical’s new drug application (NDA) submitted for …
-
Insilico and Qilu Pharmaceutical sign deal for cardiometabolic therapies
Insilico Medicine has entered a strategic partnership with Qilu Pharmaceutical and its subsidiary Shanghai Qilu Pharmaceutical Research Center on drug …
-
UK and certain European countries lose WHO’s measles-free status
The UK is one of several European countries to lose its status as measles-free amid a diminishing uptake of the …
-
Mirum acquires Bluejay Therapeutics to expand rare liver disease pipeline
Mirum Pharmaceuticals has completed the acquisition of Bluejay Therapeutics, expanding its pipeline in rare and severe liver diseases. Agreed in December …
-
FDA to review Eisai’s Leqembi Iqlik sBLA for Alzheimer’s
Eisai and Biogen have announced that the US Food and Drug Administration (FDA) has accepted for review the supplemental biologics …
-
Internet of Medical Things beats AI as top ranked growth driver among life science CEOs
A new report has revealed that 83% of life sciences CEOs view Internet of Medical Things (IoMT) devices as the …
-
UK biotechs suffered restricted financing in 2025
Both the amount of equity financing and venture capital attracted by UK biotechs dropped in 2025, compounding concerns for the …
-
MSD ends takeover talks with Revolution Medicines
Merck & Co (MSD) is no longer in talks to acquire oncology biotech Revolution Medicines after negotiations hit a stumbling …
-
NICE greenlights Pfizer’s Talzenna for NHS use
The UK’s National Institute for Health and Care Excellence (NICE) has recommended Pfizer’s Talzenna (talazoparib) in a step forward for …
-
Corxel raises $287m as obesity continues to spark investor interest
Corxel Pharmaceuticals has raised $287m to fund its suite of cardiometabolic assets, signifying that investor appetite for weight loss drug …
-
High-dose biologic delivery to become industry standard
As the pharmaceutical industry progresses further into the age of personalised medicine, next-generation, targeted and disease-modifying biologics are becoming increasingly …
-
Daiichi Sankyo and AstraZeneca’s Enhertu gains NMPA approval for HER2 GEJ
Daiichi Sankyo and AstraZeneca’s Enhertu (trastuzumab deruxtecan) has received approval from China’s National Medical Products Administration (NMPA) for adults with …
-
BMS bets on Janux’s novel solid tumour therapy through $850m deal
Bristol Myers Squibb (BMS) has added to its oncology pipeline through an exclusive global licensing agreement with Janux Therapeutics. This deal …
-
US set to officially exit WHO in culmination of Trump’s domestic push
The US is poised to leave the World Health Organization (WHO) as the one-year countdown of legal notice comes to …
